Cardiac implications for the use of  β  2 ‐adrenoceptor agonists for the management of muscle wasting | Zendy

Molenaar Peter | Zendy; Chen Lu | Zendy; Parsonage William A | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Cardiac implications for the use of β 2 ‐adrenoceptor agonists for the management of muscle wasting

Author(s) -

Molenaar Peter,

Chen Lu,

Parsonage William A

Publication year - 2006

Publication title -

british journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.432

H-Index - 211

eISSN - 1476-5381

pISSN - 0007-1188

DOI - 10.1038/sj.bjp.0706670

Subject(s) - wasting , medicine , muscle hypertrophy , skeletal muscle , cardiac muscle , adrenergic receptor , cardiac hypertrophy , agonist , endocrinology , pharmacology , receptor

There are proposals for the implementation of β 2 ‐adrenoceptor agonists for the management of muscle wasting diseases. The idea has been initiated by studies in animal models which show that β 2 ‐adrenoceptor agonists cause hypertrophy of skeletal muscle. Their use in clinical practice will also need an understanding of possible effects of activation of human heart β 2 ‐adrenoceptors. Consequences could include an increased probability of arrhythmias in susceptible patients. British Journal of Pharmacology (2006) 147 , 583–586. doi: 10.1038/sj.bjp.0706670

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research